Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

Tissue Effects in a Randomized Controlled Trial of Short-term Finasteride in Early Prostate Cancer.

Kim J, Davis JW, Klein EA, Magi-Galluzzi C, Lotan Y, Ward JF, Pisters LL, Basler JW, Pettaway CA, Stephenson A, Li Ning Tapia EM, Efstathiou E, Wang X, Do KA, Lee JJ, Gorlov IP, Vornik LA, Hoque AM, Prokhorova IN, Parnes HL, Lippman SM, Thompson IM, Brown PH, Logothetis CJ, Troncoso P.

EBioMedicine. 2016 May;7:85-93. doi: 10.1016/j.ebiom.2016.03.047. Epub 2016 Apr 7.

2.

Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial.

Lucia MS, Epstein JI, Goodman PJ, Darke AK, Reuter VE, Civantos F, Tangen CM, Parnes HL, Lippman SM, La Rosa FG, Kattan MW, Crawford ED, Ford LG, Coltman CA Jr, Thompson IM.

J Natl Cancer Inst. 2007 Sep 19;99(18):1375-83. Epub 2007 Sep 11.

PMID:
17848673
3.

Effects of short-term finasteride on apoptotic factors and androgen receptors in prostate cancer cells.

Bass R, Perry B, Langenstroer P, Thrasher JB, Dennis KL, Tawfik O, Holzbeierlein J.

J Urol. 2009 Feb;181(2):615-9; discussion 619-20. doi: 10.1016/j.juro.2008.10.029. Epub 2008 Dec 16.

PMID:
19091346
4.

PCPT: Evidence that finasteride reduces risk of most frequently detected intermediate- and high-grade (Gleason score 6 and 7) cancer.

Kaplan SA, Roehrborn CG, Meehan AG, Liu KS, Carides AD, Binkowitz BS, Heyden NL, Vaughan ED Jr.

Urology. 2009 May;73(5):935-9. doi: 10.1016/j.urology.2008.09.079. Epub 2009 Mar 28.

PMID:
19328538
5.

The effect of 3-month finasteride challenge on biomarkers for predicting cancer outcome on biopsy: Results of a randomized trial.

Hernandez J, Gelfond J, Goros M, Liss MA, Liang Y, Ankerst D, Thompson IM Jr, Leach RJ.

PLoS One. 2018 Oct 9;13(10):e0204823. doi: 10.1371/journal.pone.0204823. eCollection 2018.

6.

Detection bias due to the effect of finasteride on prostate volume: a modeling approach for analysis of the Prostate Cancer Prevention Trial.

Cohen YC, Liu KS, Heyden NL, Carides AD, Anderson KM, Daifotis AG, Gann PH.

J Natl Cancer Inst. 2007 Sep 19;99(18):1366-74. Epub 2007 Sep 11.

PMID:
17848668
7.

Effect of finasteride on serum androstenedione and risk of prostate cancer within the prostate cancer prevention trial: differential effect on high- and low-grade disease.

Hoque A, Yao S, Till C, Kristal AR, Goodman PJ, Hsing AW, Tangen CM, Platz EA, Stanczyk FZ, Reichardt JK, vanBokhoven A, Neuhouser ML, Santella RM, Figg WD, Price DK, Parnes HL, Lippman SM, Ambrosone CB, Thompson IM.

Urology. 2015 Mar;85(3):616-20. doi: 10.1016/j.urology.2014.11.024.

8.

Effect of finasteride on the sensitivity of PSA for detecting prostate cancer.

Thompson IM, Chi C, Ankerst DP, Goodman PJ, Tangen CM, Lippman SM, Lucia MS, Parnes HL, Coltman CA Jr.

J Natl Cancer Inst. 2006 Aug 16;98(16):1128-33.

PMID:
16912265
9.

Association between variants in genes involved in the immune response and prostate cancer risk in men randomized to the finasteride arm in the Prostate Cancer Prevention Trial.

Winchester DA, Till C, Goodman PJ, Tangen CM, Santella RM, Johnson-Pais TL, Leach RJ, Xu J, Zheng SL, Thompson IM, Lucia MS, Lippman SM, Parnes HL, Isaacs WB, De Marzo AM, Drake CG, Platz EA.

Prostate. 2017 Jun;77(8):908-919. doi: 10.1002/pros.23346. Epub 2017 Mar 20.

10.

Primary Gleason grade 4 at the positive margin is associated with metastasis and death among patients with Gleason 7 prostate cancer undergoing radical prostatectomy.

Viers BR, Sukov WR, Gettman MT, Rangel LJ, Bergstralh EJ, Frank I, Tollefson MK, Thompson RH, Boorjian SA, Karnes RJ.

Eur Urol. 2014 Dec;66(6):1116-24. doi: 10.1016/j.eururo.2014.07.004. Epub 2014 Jul 19.

PMID:
25052213
11.

The effects of 5alpha-reductase inhibitors on the natural history, detection and grading of prostate cancer: current state of knowledge.

Andriole G, Bostwick D, Civantos F, Epstein J, Lucia MS, McConnell J, Roehrborn CG.

J Urol. 2005 Dec;174(6):2098-104. Review.

PMID:
16280736
12.

Does long-term finasteride therapy affect the histologic features of benign prostatic tissue and prostate cancer on needle biopsy? PLESS Study Group. Proscar Long-Term Efficacy and Safety Study.

Yang XJ, Lecksell K, Short K, Gottesman J, Peterson L, Bannow J, Schellhammer PF, Fitch WP, Hodge GB, Parra R, Rouse S, Waldstreicher J, Epstein JI.

Urology. 1999 Apr;53(4):696-700.

PMID:
10197843
13.

Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers.

Xu Y, Dalrymple SL, Becker RE, Denmeade SR, Isaacs JT.

Clin Cancer Res. 2006 Jul 1;12(13):4072-9.

14.

Long-term survival of participants in the prostate cancer prevention trial.

Thompson IM Jr, Goodman PJ, Tangen CM, Parnes HL, Minasian LM, Godley PA, Lucia MS, Ford LG.

N Engl J Med. 2013 Aug 15;369(7):603-10. doi: 10.1056/NEJMoa1215932.

15.

Metastatic potential to regional lymph nodes with Gleason score ≤7, including tertiary pattern 5, at radical prostatectomy.

Diolombi ML, Epstein JI.

BJU Int. 2017 Jun;119(6):872-878. doi: 10.1111/bju.13623. Epub 2016 Sep 2.

16.

Dutasteride, the dual 5alpha-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line.

Lazier CB, Thomas LN, Douglas RC, Vessey JP, Rittmaster RS.

Prostate. 2004 Feb 1;58(2):130-44.

PMID:
14716738
17.

The intriguing role of fibroblasts and c-Jun in the chemopreventive and therapeutic effect of finasteride on xenograft models of prostate cancer.

Niu YN, Wang K, Jin S, Fan DD, Wang MS, Xing NZ, Xia SJ.

Asian J Androl. 2016 Nov-Dec;18(6):913-919. doi: 10.4103/1008-682X.167714.

18.

Prevention of prostate cancer with finasteride: US/European perspective.

Thompson IM, Klein EA, Lippman SM, Coltman CA, Djavan B.

Eur Urol. 2003 Dec;44(6):650-5. Review.

PMID:
14644115
19.

Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial.

Thompson IM, Pauler Ankerst D, Chi C, Goodman PJ, Tangen CM, Lippman SM, Lucia MS, Parnes HL, Coltman CA Jr.

J Clin Oncol. 2007 Jul 20;25(21):3076-81.

PMID:
17634486
20.

Pathologic characteristics of cancers detected in The Prostate Cancer Prevention Trial: implications for prostate cancer detection and chemoprevention.

Lucia MS, Darke AK, Goodman PJ, La Rosa FG, Parnes HL, Ford LG, Coltman CA Jr, Thompson IM.

Cancer Prev Res (Phila). 2008 Aug;1(3):167-73. doi: 10.1158/1940-6207.CAPR-08-0078. Epub 2008 May 18.

Supplemental Content

Support Center